Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer

Menopause

Volumn 22, Issue 1, 2015, Pages 17-25

  Boele, Florien W ^a   Schilder, Christina M T ^b   De Roode, Mari Lou ^c   Deijen, Jan Berend ^d   Schagen, Sanne B ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Breast cancer; Cognition; Postmenopausal; Tamoxifen

Indexed keywords

TAMOXIFEN; ANTIESTROGEN;

ADJUVANT THERAPY; ADULT; ANXIETY; ARTICLE; BRAIN FUNCTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COGNITION; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; EPISODIC MEMORY; EXECUTIVE FUNCTION; FATIGUE; FEMALE; GENOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PAIN; POSTMENOPAUSE; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RESPONSE TIME; RISK FACTOR; SLEEP DISORDER; TREATMENT DURATION; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY; ADJUVANT CHEMOTHERAPY; AGED; BREAST NEOPLASMS; DRUG EFFECTS; MEMORY DISORDER; NETHERLANDS; PHYSIOLOGY; SPEECH DISORDER;

AGED; ANXIETY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; DEPRESSION; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MEMORY DISORDERS; MIDDLE AGED; NETHERLANDS; POSTMENOPAUSE; SPEECH DISORDERS; TAMOXIFEN;

EID: 84920264580     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000271     Document Type: Article

References (46)

1. Van Nes JG, Seynaeve C, Van de Velde CJ, Nortier JW. Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole. Ned Tijdschr Geneeskd 2006;150:2863.
2. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptorjpositive breast cancer. J Clin Oncol 2010;28:3784-3796.
3. Tung N. What is the optimal endocrine therapy for postmenopausal women with hormone receptorjpositive early breast cancer? J Clin Oncol 2013;31:1391-1397.
4. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007;18(suppl 8):viii26-viii35.
5. Sherwin BB. Estrogen and cognitive aging in women. Neuroscience 2006;138:1021-1026.
6. Suzuki S, Brown CM, Wise PM. Mechanisms of neuroprotection by estrogen. Endocrine 2006;29:209-215.
7. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 2006; 27:575-605.
8. Balthazart J, Ball GF. Is brain estradiol a hormone or a neurotransmitter? Trends Neurosci 2006;29:241-249.
9. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006;116:561-570.
10. Dumas JA, Kutz AM, Naylor MR, Johnson JV, Newhouse PA. Estradiol treatment altered anticholinergic-related brain activation during working memory in postmenopausal women. Neuroimage 2012;60:1394-1403.
11. Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012;12:267-275.
12. Buwalda B, Schagen SB. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment? Life Sci 2013;93:581-588.
13. Agrawal K, Onami S, Mortimer JE, Pal SK. Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 2010;67:209-214.
14. Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer 2007;43:1342-1347.
15. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 2004;13:61-66.
16. Lejbak L, Vrbancic M, Crossley M. Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer. J Clin Exp Neuropsychol 2010; 32:836-846.
17. Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol 2008;9:953-961.
18. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;14:995-998.
19. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology 2009;18:811-821.
20. Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psycho-Oncology 2012;21:43-53.
21. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the Tamoxifen and Exemestane Adjuvant Multinational Trial. J Clin Oncol 2010;28:1294-1300.
22. Phillips KA, Ribi K, Sun Z, et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010;19:388-395.
23. Phillips KA, Aldridge J, Ribi K, et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2011;126:221-226.
24. Meulen EFJ, Schmand B, Van Campen JP, et al. The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004;75:700-705.
25. van den Burg W, Saan RJ, Deelman BG. 15-Woordentest. Provisional Manual. Groningen, the Netherlands: University Hospital; 1985.
26. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002;73:126-133.
27. Wechsler D. WMS-R: Wechsler Memory ScaleVRevised: Manual. San Antonio, TX: The Psychological Corp; 1987.
28. Wechsler D. WAIS-III Nederlandstalige bewerking. Technische handleiding. London, England: The Psychological Corp; 2000.
29. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643.
30. Armitage SG. An analysis of certain psychological tests used for the evaluation of brain injury. Psychol Monogr 1946;60:i.
31. Alpherts W, Aldenkamp AP. FePsy: The Iron Psyche. Heemstede, the Netherlands: Instituut voor Epilepsiebestrijding; 1994.
32. Luteijn F, Van der Ploeg FAE. Handleiding Groninger intelligentietest (GIT) [Manual Groningen Intelligence Test]. Lisse, the Netherlands: Swetz and Zeitlinger; 1983.
33. Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J. Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 2006;12:80-89.
34. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
35. Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer Breast CancerYSpecific Quality-of-Life Questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14:2756-2768.
36. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999;55:187-197.
37. Fröjdh K, Hakansson A, Karlsson I. The Hopkins Symptom Checklist-25 is a sensitive case-finder of clinically important depressive states in elderly people in primary care. Int J Geriatr Psychiatry 2004;19:386-390.
38. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010;28:4434-4440.
39. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006; 15:422-430.
40. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26:955-969.
41. Legault C, Maki PM, Resnick SM, et al. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: Cognition in the Study of Tamoxifen and Raloxifene. J Clin Oncol 2009;27:5144-5152.
42. Hermelink K, Küchenhoff H, Untch M, et al. Two different sides of chemobrain: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psycho-Oncology 2010;19:1321-1328.
43. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11:6-15.
44. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancertherapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-629.
45. Maki PM. Hormone therapy and cognitive function: is there a critical period for benefit? Neuroscience 2006;138:1027-1030.
46. Newhouse P, Albert K, Astur R, Johnson J, Naylor M, Dumas J. Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women. Neuropsychopharmacology 2013;38: 2632-2643.